Overall impact
B (66)

Commentary

DiaSorin is a strong overall performer. With a 'B' rating of 65.5 for overall impact (74th percentile compared to all companies), DiaSorin ranks 38th out of 76 industry peers, behind IMAC, Enzo Biochem, Invitae and 34 others, and ahead of Check-Cap, Organovo, Joinn Laboratories and 35 others. On top material causes for DiaSorin's industry (Healthcare Software & Services), DiaSorin performs well in Technology Innovation (95.5 score) and performs poorly in Quality Lifelong Education (31.1 score).
Impact
Cause DSRLF
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
3,260
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Vc, Italy
Share classes
DSRLF
Description
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Material causes
Ethos considers the following causes material for DiaSorin, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.